莱卡尼马布偏好地与阿尔茨海默氏症早期存在的较小聚合物结合
Emre Fertan1,2, Jeff Y L Lam1,2,3, Giulia Albertini4
1Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
概括
莱卡尼马布有效地与阿尔茨海默氏症早期阶段的粉样β聚合物结合,解释了其临床成功. 这表明Lecanemab在患有早期疾病的患者中最有效.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 生物化学 生化学
背景情况:
- 阿尔茨海默病 (AD) 治疗包括单克隆抗体,如阿杜卡努马布,莱卡内马布,甘特内马布和多纳内马布.
- 粉样β (Aβ) 聚合物是AD治疗的关键标.
研究的目的:
- 描述四个单克隆抗体与可扩散的粉样β聚合物的结合.
- 了解抗体结合特征与阿尔茨海默病治疗成功之间的关系.
主要方法:
- 使用单分子检测和超高分辨率成像.
- 对抗体结合的评估是使用体外生成和人类大脑衍生的Aβ聚合物.
主要成果:
- 莱卡尼马布对小型,可扩散的Aβ聚合物具有优越的结合,具有高亲和力和有效的聚合物涂层.
- 可扩散的Aβ聚合物的数量和大小随着布拉克阶段的增加而增加.
- 莱卡尼马布优先结合于较小的聚合物,这些聚合物在早期疾病阶段更为丰富.
结论:
- 莱卡涅马布对早期Aβ聚合物的强烈结合解释了其临床试验的成功.
- 莱卡尼马布在治疗阿尔茨海默氏症早期阶段可能更有效.
相关概念视频
01:26Alzheimer's Disease: Overview
328
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
328
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128